The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.

Farlow, Andrew; Torreele, Els; Gray, Glenda; Ruxrungtham, Kiat; Rees, Helen; Prasad, Sai; Gomez, Carolina; Sall, Amadou; Magalhães, Jorge; Olliaro, Piero; Terblanche, Petro

Farlow, Andrew; Torreele, Els; Gray, Glenda; Ruxrungtham, Kiat; Rees, Helen; Prasad, Sai; Gomez, Carolina; Sall, Amadou; Magalhães, Jorge; Olliaro, Piero; Terblanche, Petro.

Afiliação

Farlow A; Nuffield Department of Medicine, University of Oxford, Broad St., Oxford OX1 3BD, UK.
Torreele E; Oxford Martin School, University of Oxford, Broad St., Oxford OX1 3BD, UK.
Gray G; Independent Consultant and Institute for Innovation & Public Purpose (IIPP), University College London, London WC1E 6BT, UK.
Ruxrungtham K; Office of the President, South African Medical Research Council (SAMRC), Tygerberg 7050, South Africa.
Rees H; Center of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Bangkok 10330, Thailand.
Prasad S; School of Global Health (SGH), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Gomez C; Wits RHI, University of Witwatersrand, Johannesburg 2050, South Africa.
Sall A; Bharat Biotech International Limited, Genome Valley, Shameerpet, Hyderabad 500 078, India.
Magalhães J; Facultad de Derecho, Universidad Nacional de Colombia, Cra 45, Bogotá 111321, Colombia.
Olliaro P; Virology Department, Institut Pasteur de Dakar, 36, Avenue Pasteur, Dakar 10200, Senegal.
Terblanche P; Centre for Technological Innovation, Institute of Drugs Technology-Farmanguinhos, Oswaldo Cruz Foundation, Rio de Janeiro 21041-210, Brazil.

Vaccines (Basel) ; 11(3)2023 Mar 17.

Article em En | MEDLINE | ID: mdl-36992275

Palavras-chave

COVAX; COVID-19 vaccine lessons; R&D blueprints; controlling transmission; disease X and pathogen X; epidemic and pandemic prevention; low- and middle-income country (LMIC) vaccine innovation and manufacture; mRNA); modular vaccine production; mucosal immunity; pan-coronavirus vaccines; platform technologies (esp. inactivated viruses; public investments and subsidies; recombinant proteins; regulatory challenges; technology global commons and global public goods; vaccine access; vaccine business model and value proposition; vaccine intellectual property (IP) and know-how transfer; vaccine prototypes; variants and booster strategies; viral vectors

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 Problema de saúde: 1_geracao_evidencia_conhecimento / 1_medicamentos_vacinas_tecnologias Tipo de estudo: Clinical_trials / Qualitative_research Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google